Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Nexalin Technology, Inc. Director's Dealing 2025

Jan 24, 2025

35042_dirs_2025-01-24_42c2f63b-df54-47fe-aec5-8815196ca877.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nexalin Technology, Inc. (NXL)
CIK: 0001527352
Period of Report: 2025-01-13

Reporting Person: Owens David (Director, Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-01-13 Common stock P 2000 $2.50 Acquired 151293 Direct
2025-01-23 Common stock P 1000 $2.70 Acquired 152293 Direct